Low energy. Slower recovery. A drive that isn't what it used to be. For many men, these aren't just signs of getting older — they can be signs that testosterone levels have quietly declined. Testosterone replacement therapy (TRT) is designed to restore those levels under physician guidance, supporting the energy, strength, and vitality your body is built for.

At Calibrate IV, we take an evidence-first approach to hormone optimization. Here's what the current clinical research actually shows — including where the science is strong, and where it's still evolving.

What the Research Shows

Cardiovascular Safety: A Major Shift in the Data

For years, testosterone therapy carried a black-box warning over cardiovascular concerns. That changed with the TRAVERSE trial, a large randomized, placebo-controlled human study that tracked cardiovascular outcomes in hypogonadal men on TRT. The results were significant enough that the FDA removed the black-box warning from testosterone products in March 2025, after the trial found that appropriately administered TRT did not elevate cardiovascular risk in the population studied.

Energy, Mood, and Quality of Life

Secondary analyses from the same trial, along with the earlier T-Trials research program, found that men on TRT reported modest but statistically meaningful improvements in energy and mood compared to placebo, sustained out to 24 months. It's worth being precise here: researchers describe these effects as modest, not dramatic — testosterone therapy is a support for vitality, not a cure-all, and results vary by individual. A 2024 UK-based evidence synthesis (the TestES review, covering 35 studies and over 5,600 participants) echoed this nuance, noting that while men with low testosterone commonly report low mood and fatigue, not every study has shown these symptoms reliably improve with treatment — underscoring why individualized, physician-guided assessment matters more than a one-size-fits-all approach.

Muscle, Strength, and Body Composition

Human clinical studies in aging men have documented improvements in muscle mass, strength, and bone density with testosterone therapy, alongside benefits to sexual function. A 2025 narrative review of TRT in men 50 and older, drawing on randomized controlled trials, cohort studies, and meta-analyses, found consistent support for these outcomes in carefully selected patients — while also noting that benefits are population-dependent and require proper candidate screening.

Safety Monitoring Still Matters

None of this means TRT is without considerations. Erythrocytosis (elevated red blood cell counts) remains the most commonly reported effect of testosterone therapy, which is why ongoing hematocrit monitoring is a standard part of physician-supervised treatment. This is exactly why TRT should never be self-directed — it's a therapy that works best with real clinical oversight.

How Calibrate IV Approaches Testosterone Therapy

Every Calibrate IV testosterone program starts with a real hormone panel, not a guess. Our physician-guided team reviews your bloodwork, symptoms, and health history before building a personalized plan — then monitors your levels along the way, so your therapy adjusts as your body responds. No waiting rooms, no generic protocols — just clinical care that's built around you.

This content is for educational purposes and is not a substitute for individualized medical advice. Testosterone therapy is available only through physician evaluation.

References

1. Bhasin S, et al. Depressive syndromes in men with hypogonadism in the TRAVERSE trial: response to testosterone-replacement therapy. J Clin Endocrinol Metab. 2024. (Human RCT)
2. Zitzmann M, et al. Cardiovascular safety of testosterone therapy — insights from the TRAVERSE trial. Andrology. 2026. (Human RCT / expert position statement)
3. Grossmann M, Anawalt BD, Yeap BB. Testosterone therapy in older men: clinical implications of recent landmark trials. Eur J Endocrinol. 2024;191(1):R22–R31. (Human RCT review)
4. Cruickshank M, et al. The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation. Health Technol Assess. 2024;28(43):1–210. (Human systematic review/meta-analysis, 35 studies, 5,601 participants)
5. Narrative review: Testosterone Replacement Therapy in Men Aged 50 and Above — Evidence-Based Benefits, Safety Considerations, and Clinical Recommendations. PMC, 2025. (Human RCT/cohort/meta-analysis review)